Uncategorized Archives - Page 5 of 145

WednesdayAug 27, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology

Growing clinical evidence supports the expanding role of mobile and home-based ECG capture in improving patient outcomes. HeartBeam’s proprietary system offers a cable-free design that allows for high-fidelity ECG measurements without the complexity of conventional equipment. Portable, credit card-sized design enables patients to record symptoms at home or wherever they are. Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct…

TuesdayAug 26, 2025 12:00 pm

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch

The company's rebranding reflects Izotropic's refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem Izotropic's strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 (ibn.fm/tRIr4), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing…

TuesdayAug 26, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones. Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments. The company's pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas. With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to…

MondayAug 25, 2025 1:15 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential. Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers. Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent. Enhancements to RADR(R), the company’s AI platform, include public launch of predictBBB.ai(TM) and a new drug combination module. Lantern ended Q2 with $15.9 million in cash and expects its runway to extend into mid-2026. R&D expenses declined year-over-year, reflecting disciplined cost control while advancing multiple trials.…

FridayAug 22, 2025 12:00 pm

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from ketamine products. The preservative has known toxicity and is no longer allowed in hand sanitizers or topical antiseptics. Ketamine is increasingly used off-label for treating suicidal depression and PTSD. The company argues repeated exposure to benzethonium chloride through IV use poses unnecessary health risks. NRx has submitted data showing its preservative-free ketamine maintains sterility and stability for three years. The company is pursuing FDA approval for both its preservative-free ketamine (“NRX-100”) and oral NMDA-targeting drug (“NRX-101”). NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has…

ThursdayAug 21, 2025 12:45 pm

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Clene Inc. plans to submit a New Drug Application (“NDA”) for lead candidate CNM-Au8® in ALS by year-end 2025. FDA meetings scheduled in Q3 2025 will address ALS survival benefit data and MS development plans. Neurofilament light biomarker data analysis from the NIH-sponsored EAP program is expected in early Q4 2025. The company reported $7.3 million in cash and cash equivalents as of June 30, 2025, together with recent financing extending the company’s cash runway into Q1 2026. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and…

WednesdayAug 20, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic…

TuesdayAug 19, 2025 9:45 am

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability. The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning. Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery. Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach. The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development. Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance…

TuesdayAug 19, 2025 9:45 am

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast…

FridayAug 15, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy

Ricin toxin is a potent biothreat, so lethal that even a dose the size of a grain of salt can be fatal within 48 to 72 hours. RiVax(R) is a subunit protein vaccine that incorporates Soligenix’s ThermoVax(R) technology, which eliminates the need for cold-chain storage. Soligenix reports that the RiVax antigen has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies. With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search